Related Experiment Video

Updated: Aug 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Uric acid levels and vascular disease

S S Daskalopoulou1, V G Athyros, M Elisaf

  • 1Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Royal Free and University College Medical School, London, UK.

Current Medical Research and Opinion
|June 18, 2004
PubMed

Insights

Serum uric acid (SUA) levels are linked to vascular event risk. Lowering SUA through common medications may significantly reduce vascular disease and mortality, supported by trial data.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Serum uric acid (SUA) levels are recognized as a predictor of vascular events.
  • Previous studies, such as the LIFE trial, suggest a link between reduced SUA and improved cardiovascular outcomes.
  • The GREACE study also provides insights into the relationship between SUA levels and treatment strategies.

Purpose of the Study:

  • To examine the SUA-lowering effects of commonly prescribed medications for vascular disease.
  • To discuss how these reductions might impact vascular morbidity and mortality.
  • To propose that judicious drug use can lead to significant reductions in vascular risk.

Main Methods:

  • Review of findings from completed clinical trials, including the LIFE and GREACE studies.
  • Discussion of the SUA-lowering effects of various drug classes (statins, fibrates, antihypertensives).
  • Consideration of potential benefits from combining different therapeutic agents.

Main Results:

  • Evidence suggests that SUA levels predict vascular event risk.
  • A significant portion of outcome improvements in trials like LIFE can be attributed to SUA reduction.
  • Commonly prescribed drugs, including statins and antihypertensives, can lower SUA levels.

Conclusions:

  • Judicious use of medications, alone or in combination, can achieve modest reductions in SUA.
  • These SUA reductions may translate into substantial decreases in vascular event risk.
  • Further prospective studies are needed to confirm the association between SUA lowering and reduced vascular morbidity and mortality.

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...